Lunai Bioworks (STU:2Q5) Total Operating Expense: €8.49 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2Q5 Lunai Bioworks Inc STU:2Q5
26 GF Score
Price €8.37
! 6 Warning Signs
View Full Analysis

What is Lunai Bioworks Total Operating Expense?

Lunai Bioworks STU:2Q5 26 Total Operating Expense is €8.49 Mil as of Mar. 2026. GuruFocus rates STU:2Q5 with a GF Score™ of 26/100. The stock has 6 warning signs investors should review.

Lunai Bioworks's Total Operating Expense for the three months ended in Mar. 2026 was €1.25 Mil. Lunai Bioworks's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €8.49 Mil.

Lunai Bioworks Total Operating Expense Related Terms

Lunai Bioworks Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Lunai Bioworks's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lunai Bioworks Total Operating Expense Chart

Lunai Bioworks Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.42 21.59 18.09 25.44 16.08

Lunai Bioworks Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.85 3.57 2.11 1.56 1.25
STU:2Q5
26GF Score
Lunai Bioworks Inc STU:2Q5
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lunai Bioworks Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €8.49 Mil mean?
Lunai Bioworks (STU:2Q5) has a Total Operating Expense of €8.49 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Lunai Bioworks and its competitors.
Is Lunai Bioworks' Total Operating Expense too high?
Lunai Bioworks' current Total Operating Expense is €8.49 Mil. Overall, Lunai Bioworks has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lunai Bioworks' Total Operating Expense compare to BCLI and BIVI?
Lunai Bioworks' Total Operating Expense of €8.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Lunai Bioworks and its competitors. Lunai Bioworks's current Total Operating Expense is €8.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lunai Bioworks stock overvalued right now?
Lunai Bioworks (STU:2Q5) has a current Total Operating Expense of €8.49 Mil. The current Total Operating Expense is €8.49 Mil. Lunai Bioworks' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Lunai Bioworks (STU:2Q5), the current Total Operating Expense is €8.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lunai Bioworks Business Description

Other Exchanges LNAI:USA
Address 2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
26GF Score

Get the complete analysis for STU:2Q5

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.37
Price